Drug intelligence / Profile preview

Dermol 500

Development stage
Unknown
Lead developer
Diomed Developments
Modality
Small Molecules
Administration
Topical
01

Overview

Dermol 500 is an antimicrobial emollient lotion developed by Dermal Laboratories for the management of dry and pruritic skin conditions, including eczema and dermatitis. It is formulated with four active ingredients: benzalkonium chloride and chlorhexidine dihydrochloride, which provide broad-spectrum antimicrobial activity by disrupting bacterial cell membranes, and liquid paraffin and isopropyl myristate, which act as emollients to moisturize the skin and reinforce the epidermal barrier. The product is designed to reduce skin colonization by pathogens like *Staphylococcus aureus* while preventing moisture loss. In addition to its use as a leave-on emollient, it can be used as a soap substitute. It has also been investigated in Phase 4 clinical trials for the prevention of pin site infections following circular frame orthopedic surgery.

Brand names
Dermol 500Dermol500Dermol-500Dermol 500 LotionDermol500 LotionDermol-500 Lotion
02

Targets

Viral lipid envelopeStratum corneum lipids

Beyond the preview

Go deeper on Dermol 500.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dermol 500.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call